Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03513562
Title Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Recruitment Unknown status
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ohio State University Comprehensive Cancer Center

chronic lymphocytic leukemia


Ibrutinib + Venetoclax

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.